Thuong-Thuong Nguyen, MD
Obstetrics/Gynecology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Offices
- 2
Offices
2 locations · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Nguyen’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A105349 · Current
Licensed to practise in California · since 2008 · expires 2027-11-30 · Georgetown University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Medicaid work
$1,330,813 in 2024
Medicaid paid $1,330,813 for 20,853 billed services this clinician did in 2024, up to 226 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 2,458 | $1,289,273 |
| Short return visit (20+ min) | 1,929 | $5,683 |
| OBSTETRICAL CARE | 17 | $5,616 |
| Return visit (30+ min) | 686 | $4,459 |
| Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis | 172 | $4,264 |
| Infectious agent detection by nucleic acid (DNA or RNA); Candida species, amplified probe technique | 177 | $2,483 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 397 | $2,066 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 397 | $2,053 |
| Prenatal care, at-risk enhanced service; education | 249 | $1,959 |
| Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use | 48 | $1,515 |
| Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique | 177 | $1,216 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 125 | $1,124 |
| 2024 | 20,853 | 64 | 226 | $1,330,813 |
| 2023 | 7,155 | 32 | 206 | $1,207,344 |
| 2022 | 5,677 | 28 | 222 | $993,147 |
| 2021 | 4,625 | 23 | 182 | $917,953 |
| 2020 | 8,036 | 37 | 287 | $1,276,069 |
| 2019 | 7,586 | 29 | 296 | $1,379,434 |
| 2018 | 3,193 | 21 | 221 | $717,042 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 2,344 | $1,199,826 |
| Short return visit (20+ min) | 1,684 | $2,415 |
| Return visit (30+ min) | 646 | $1,295 |
| Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis | 84 | $615 |
| Ultrasound, pregnant uterus, real time with image documentation, limited (eg, fetal heart beat, placental location, fetal position and/or qualitative amniotic fluid volume), 1 or more fetuses | 16 | $507 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 115 | $473 |
| FETAL NON-STRESS TEST | 35 | $369 |
| Infectious agent detection by nucleic acid (DNA or RNA); Candida species, amplified probe technique | 87 | $364 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 158 | $303 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 157 | $302 |
| Prenatal care, at-risk enhanced service; education | 86 | $225 |
| Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique | 87 | $209 |
2022
| Clinic visit/encounter, all-inclusive | 1,971 | $985,296 |
| Short return visit (20+ min) | 1,067 | $2,360 |
| Return visit (30+ min) | 623 | $1,716 |
| OBSTETRICAL CARE | 14 | $1,470 |
| Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use | 28 | $708 |
| Prenatal care, at-risk enhanced service; education | 142 | $569 |
| Short return visit | 150 | $295 |
| Patient education, not otherwise classified, non-physician provider, individual, per session | 29 | $108 |
| Long return visit (40+ min) | 21 | $105 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 17 | $91 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 17 | $91 |
| FETAL NON-STRESS TEST | 16 | $86 |
2021
| Clinic visit/encounter, all-inclusive | 1,894 | $912,849 |
| Short return visit | 679 | $1,768 |
| Short return visit (20+ min) | 464 | $1,437 |
| Return visit (30+ min) | 351 | $1,023 |
| Prenatal care, at-risk enhanced service; education | 93 | $277 |
| Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68), pooled result | 12 | $154 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 30 | $123 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 30 | $123 |
| Preventive medicine counseling and risk factor reduction intervention for individual, approximately 15 minutes | 52 | $108 |
| Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with screening by automated system and manual rescreening or review, under physician supervision | 28 | $39 |
| URINE PREGNANCY TEST | 125 | $36 |
| Patient education, not otherwise classified, non-physician provider, individual, per session | 18 | $15 |
2020
| Clinic visit/encounter, all-inclusive | 3,301 | $1,262,881 |
| Payment for communication technology-based services for 5 minutes or more of a virtual (non-face-to-face) communication between an rural health clinic (rhc) or federally qualified health center (fqhc) practitioner and rhc or fqhc patient, or 5 minutes or more of remote evaluation of recorded video and/or images by an rhc or fqhc practitioner, occurring in lieu of an office visit; rhc or fqhc only | 331 | $5,147 |
| Short return visit (20+ min) | 1,676 | $4,248 |
| Return visit (30+ min) | 541 | $1,094 |
| Short return visit | 399 | $762 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 204 | $414 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 203 | $413 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 116 | $253 |
| Unclassified drugs | 12 | $207 |
| Patient education, not otherwise classified, non-physician provider, individual, per session | 70 | $182 |
| TREPONEMA PALLIDUM | 125 | $109 |
| Prenatal care, at-risk enhanced service; education | 26 | $62 |
2019
| Clinic visit/encounter, all-inclusive | 3,450 | $1,366,647 |
| OBSTETRICAL CARE | 15 | $3,913 |
| Service | 87 | $1,884 |
| Return visit (30+ min) | 523 | $1,762 |
| Short return visit (20+ min) | 1,509 | $1,637 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 324 | $1,272 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 322 | $1,268 |
| New patient visit (30+ min) | 14 | $194 |
| TREPONEMA PALLIDUM | 189 | $186 |
| Infectious agent enzymatic activity other than virus (eg, sialidase activity in vaginal fluid) | 87 | $177 |
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result | 75 | $110 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Trichomonas vaginalis | 72 | $93 |
2018
| Clinic visit/encounter, all-inclusive | 1,868 | $710,261 |
| Service | 124 | $2,686 |
| Short return visit (20+ min) | 452 | $1,036 |
| Return visit (30+ min) | 223 | $893 |
| Ultrasound, pregnant uterus, real time with image documentation, limited (eg, fetal heart beat, placental location, fetal position and/or qualitative amniotic fluid volume), 1 or more fetuses | 13 | $523 |
| FETAL NON-STRESS TEST | 48 | $500 |
| Service | 28 | $374 |
| Unclassified drugs | 34 | $315 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 110 | $200 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 110 | $199 |
| Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group B, amplified probe technique | 12 | $42 |
| Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with screening by automated system and manual rescreening or review, under physician supervision | 45 | $8 |
Money from drug and device companies
$16 in 2025
| 2025 | 1 | 1 | None | $16 |
| 2024 | 1 | 1 | None | $20 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Organon | None | $16 | 1 payment
|
See the published payment
| Organon | Meals · 2025-10-24 | None | $16 |
See earlier years (2024)
2024: $20
| Mayne Pharma Commercial | None | $20 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1215119888
- Licence
- CA A105349California A105349: Current · expires 2027-11-30
- Trained
- Georgetown University School of Medicine, 2007
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 1083 N Hillview Dr, Milpitas, CA, 95035
- NPI first listed
- 2007-12-05
- NPI last updated
- 2022-04-02
- NPI record certified
- 2022-04-01
This is when the NPI record was last certified, not a medical board exam.